Life Sciences
Lunit and Capio S:t Göran Hospital Collaborate to Address Radiologist Shortage with AI-Powered Mammography Analysis
Lunit a leading global provider of AI-powered cancer diagnostic solutions,announced the signing of a supply and license agreement with Capio S:t Göran…

Lunit a leading global provider of AI-powered cancer diagnostic solutions,announced the signing of a supply and license agreement with Capio S:t Göran Hospital, Stockholm, Sweden.
Capio S:t Göran Hospital is Sweden’s largest private hospital with over 2,300 medical staff. It is operated by Capio, a part of the Ramsay Santé group. The hospital delivers both planned and emergency medical care services to 100,000 patients from the region of Stockholm.
The integration of Lunit’s AI solution will enable Capio S:t Göran Hospital to analyze approximately 78,000 patients’ mammography images each year, significantly contributing to Sweden’s national cancer screening program.
Recommended: Embrace AI to become a W.I.T.C.H. Leader
Sweden currently struggles with a pronounced shortage of radiologists, posing challenges to efficient mammography analysis. In response, Lunit INSIGHT MMG is poised to play a pivotal role in addressing this shortage and enhancing the efficacy of cancer screening programs. By harnessing the power of artificial intelligence, the solution assists radiologists in accurately interpreting mammography images, alleviating the burden on limited resources.
This collaboration introduces an advancement where, for the very first time, AI takes on the role of interpreting mammograms as an independent reader in a structural and validated setting. By leveraging AI technology in a safe, scalable, and effective manner, this innovative approach not only enhances productivity but also reduces the necessary workforce by half in the double screening setting.
The decision to adopt Lunit INSIGHT MMG by S:t Göran Hospital was bolstered by the results of the world’s first prospective medical AI study. Led by Dr. Fredrik Strand at Karolinska University Hospital. The study examined data from 55,581 Swedish women provided by S:t Göran Hospital. The study demonstrated that the combined analysis of one radiologist and AI, achieved higher cancer detection rates and lower recall rates compared to the analysis performed by two radiologists.
“This innovative step to becoming the world’s first breast center using AI as an independent reader, allows radiologists to be less burdened from the excessive amount of reading, enabling them to focus on more advanced diagnostics and ensuring shorter waiting times for patients,” said Dr. Karin Dembrower, Senior Physician of Capio S:t Göran Hospital Mammography Clinic, locally responsible for the study. “In the short term, we anticipate detecting more cancers; in the long term, we envision a decrease in interval cancers and the detection of smaller tumors. We are excited to conduct further studies to explore these possibilities.”
Recommended: AiThority Interview with Arijit Sengupta, CEO and Founder at Aible
“We are delighted to partner with Capio S:t Göran Hospital and be part of their innovating efforts in transforming cancer screening workflows,” said Brandon Suh, CEO of Lunit. “This collaboration represents a significant milestone in leveraging AI technology to address the radiologist shortage in Sweden. Lunit INSIGHT MMG has the potential to revolutionize mammography analysis, make a substantial contribution to the national cancer screening program, and ultimately improve patient outcomes as well.”
Lunit remains committed to forging partnerships with medical institutions across Europe, offering advanced medical experiences for patients and enhancing operational efficiency for hospitals.
Top AI ML Insights: AiThority Interview with Alex Mans, Founder and CEO at FLYR Lab
[To share your insights with us, please write to sghosh@martechseries.com]
The post Lunit and Capio S:t Göran Hospital Collaborate to Address Radiologist Shortage with AI-Powered Mammography Analysis appeared first on AiThority.

Cybin Completes Dosing in Phase 2 Study of CYB003 for the Treatment of Major Depressive Disorder
–Topline efficacy data expected in Q4 2023 – – Preparations are underway to scale the CYB003 program to a potential Phase 3 study in early 2024 –…
Ipsen updates on QM-1114 regulatory process
PARIS, FRANCE, 3 October 2023 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that its…
The post Ipsen updates on QM-1114 regulatory process first…
NIH ‘High Risk-High Reward’ grants go to two UF Health researchers exploring strategies to fight cancer and other diseases
GAINESVILLE, Fla. — Two University of Florida Health researchers have received prestigious High Risk-High Reward grants from the National Institutes…
-
Medtech15 hours ago
Wayve Releases GAIA-1 Technical Report to Advance World Models for Autonomy
-
Wellness15 hours ago
The New Hipster Starter Pack
-
Life Sciences7 hours ago
NIH ‘High Risk-High Reward’ grants go to two UF Health researchers exploring strategies to fight cancer and other diseases
-
Medtech20 hours ago
Sustainable Cityscapes: Can AI Create Greener and More Sustainable Cities?
-
Medtech19 hours ago
New biobanking partnership safeguards the genetic diversity of America’s endangered species
-
Markets11 hours ago
Shocking stocks: Sunrun Inc (NASDAQ:RUN), Rite Aid Corp. (NYSE:RAD)
-
Markets10 hours ago
Dazzling stocks: Roivant Sciences Ltd (NASDAQ:ROIV), Emergent Biosolutions Inc (NYSE:EBS)
-
Markets11 hours ago
Charming stocks: Vroom Inc. (VRM -2.68%), Xeris Biopharma Holdings Inc (XERS -5.91%)